5-Amino-1MQ
Research OnlyA small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
5-Amino-1-Methylquinolinium · NNMT Inhibitor
Mostly preclinical · 1 human study
- Preclinical
- 92%
- Human research
- 8%
Based on 12 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of 5-Amino-1MQ are based entirely on animal and in vitro studies. No human mechanistic data exists.
How It Works (Simplified)
5-Amino-1MQ acts by blocking NNMT, an enzyme that depletes important cellular resources:
Blocks NNMT enzyme activity, preventing it from consuming NAD+ precursors and SAM (the universal methyl donor).
Preserves nicotinamide for NAD+ synthesis, increasing cellular NAD+ levels especially in adipose tissue.
Higher NAD+ activates sirtuins (SIRT1-7), master regulators of metabolism, mitochondrial function, and energy expenditure.
In mice, leads to increased energy expenditure, adipose browning, and weight loss without reduced food intake.
Key Research: Neelakantan H et al. (UTMB, 2018) demonstrated that a potent, selective small-molecule NNMT inhibitor significantly reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake. PMID:29155147
Important Limitations
- Zero human trials - All efficacy data is from mice only
- Translation to human adipose tissue metabolism is unconfirmed
- Human pharmacokinetics (absorption, half-life, dosing) completely unknown
- NNMT expressed in multiple tissues (liver, brain, muscle) - systemic effects uncharacterized
- Potential cardiovascular concerns from vascular NNMT inhibition (NNMT may protect endothelium)
- No long-term safety data in any species
Based on preclinical data: NNMT inhibition should begin immediately upon administration. Mouse studies dosed NNMT inhibitors over multi-week treatment periods. No human pharmacokinetic data available to predict onset.
PMID:29155147In mouse studies, significant body-weight and white-adipose-mass reduction observed with NNMT-inhibitor treatment. Increased adipocyte NAD+ documented. Human timeline completely unknown.
PMID:29155147No long-term preclinical studies available. Sustained effects, tolerance development, and long-term metabolic adaptations are uncharacterized.
Completely unknown. Long-term safety and efficacy data do not exist in any species. Chronic NNMT inhibition effects unstudied.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Nmn
SynergisticTheoretical synergy: NMN provides NAD+ precursor while 5-Amino-1MQ preserves NAD+ by blocking NNMT consumption. Both aim to elevate NAD+ through complementary mechanisms. No combined studies available.
Nicotinamide-Riboside
SynergisticSimilar theoretical synergy as NMN. NR provides substrate for NAD+ synthesis while 5-Amino-1MQ reduces NAD+ depletion. Combined effects unstudied.
AOD-9604
CompatibleDifferent mechanisms of action (5-Amino-1MQ targets NNMT/NAD+ pathway vs AOD-9604's lipolytic effects). No interaction studies available; both target metabolic pathways through distinct routes.
Resveratrol
CompatibleBoth activate sirtuin pathways - resveratrol directly, 5-Amino-1MQ indirectly via NAD+ elevation. Theoretically complementary but unstudied.
Semaglutide
CautionBoth target metabolic and weight management pathways. Semaglutide is a GLP-1 agonist affecting appetite/insulin while 5-Amino-1MQ targets cellular NAD+ metabolism. No interaction data exists.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare 5-Amino-1MQ
Related Peptides
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
Cagrilintide
AM833 · NN9838
Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Ecnoglutide
XW003 · Sciwind GLP-1
A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
Liraglutide
Victoza · Saxenda · NN2211
The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.
Compared With
16 comparisonsConditions Studied
3 entries- 5-Amino-1MQ for Obesity 5-Amino-1MQ has been studied in diet-induced obese mouse models. Treatment reduced body weight without decreasing food intake, sug…
- 5-Amino-1MQ for Metabolic Syndrome Preclinical studies show NNMT inhibition improves insulin sensitivity and glucose tolerance in mice. Human observational data show…
- 5-Amino-1MQ for Fatty Liver (NAFLD) Liver-specific NNMT knockdown reduced hepatic steatosis in mice via Sirt1 activation. 5-Amino-1MQ's effects on liver specifically…